ID
45669
Description
Principal Investigator: Andy Futreal, PhD, UT MD Anderson Cancer Center, Houston, TX, USA MeSH: Melanoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001257 Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-γ, which is a critical cytokine for host immune responses. However, the role of IFN-γ signaling in tumor cells in the setting of anti-CTLA-4 therapy remains unknown. Here we demonstrate that, based upon exome sequencing data, patients identified as non-responders to anti-CTLA-4 (ipilimumab) harbor a much higher genomic defects in the IFN-γ pathway genes than melanoma patients who had clinical response to ipilimumab therapy.
Link
Keywords
Versions (1)
- 4/2/23 4/2/23 - Simon Heim
Copyright Holder
Andy Futreal, PhD, UT MD Anderson Cancer Center, Houston, TX, USA
Uploaded on
April 2, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001257 Genetic Analysis of Tumor Samples
The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, response upon anti-CTLA4 treatment or IFNgamma-stimulation, sex, and disease onset age.
- This sample attributes table contains sample IDs, sample type, analyte type, tumor status, histological type, tumor treatment, and name of the center which conducted sequencing.
Similar models
The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, response upon anti-CTLA4 treatment or IFNgamma-stimulation, sex, and disease onset age.
- This sample attributes table contains sample IDs, sample type, analyte type, tumor status, histological type, tumor treatment, and name of the center which conducted sequencing.
C0441833 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])